Innovations in weight management include development of biodegradable fat-absorbing microbeads inspired by boba pearls, composed of compounds derived from green tea and brown seaweed. These microbeads exhibit up to 81% absorption efficiency of dietary fats in vitro and reduced weight gain in rats on high-fat diets, potentially mitigating side effects common to orlistat. Separately, Novo Nordisk's obesity drug Wegovy has achieved significant regulatory milestones, with ongoing efforts to optimize patient identification and disease monitoring to maximize real-world impact.